Abstract: An object of the present invention is to establish means for providing a component vaccine which can selectively or intensively induce cell-mediated immunity mainly attributable to MHC class I, and humoral immunity mainly attributable to MHC class II. The inventors have found that the object can be attained by providing a component vaccine containing, as an active ingredient, a trimer and/or a hexamer of a molecular needle carrying a peptide binding to MHC class I and/or a peptide binding to MHC class II. The inventors have also found an information acquisition method that can determine the MHC class or the like of a test peptide or a similar substance by detecting a change in secretion of a physiologically active substance such as a cytokine in a test animal which has been infected with a target microorganism.

Abstract: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.

Abstract: An object of the present invention is to establish means for providing a component vaccine which can elicit immunity to a non-structural protein. The present inventors have found that the object can be attained by providing a component vaccine containing an associated product containing a trimer and/or a hexamer of a molecular needle to which a non-structural protein of a pathogenic virus is attached.